{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:27:03Z","timestamp":1787776023544,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>Guidelines for primary care clinicians on monitoring and safety guidelines regarding Janus kinase and tyrosine kinase 2 inhibitors in the treatment of inflammatory skin conditions are often unclear. This review aims to provide the primary care physician with a review of clinically relevant and updated information regarding the monitoring and overall profile of these medications. To do so, a systematic review was conducted using the PubMed database and relevant Food and Drug Administration (FDA) approved drug inserts from manufacturers. Janus kinase and tyrosine kinase 2 inhibitors have recently gained FDA approval for the treatment of several inflammatory skin conditions including atopic dermatitis, plaque psoriasis, alopecia areata, and vitiligo. There is a known box warning associated with the Janus kinase inhibitors that create the need for monitoring and close follow-up while patients are undergoing these treatments. Although these medications are often prescribed by specialists, as their use becomes more prevalent and therapies continue to gain approval for the treatment of these commonly encountered conditions, it is important for the primary physician to be updated and aware of the current monitoring guidelines and safety profile for this class of medication. Both Janus kinase inhibitors and tyrosine kinase 2 inhibitors display significant efficacy in the treatment of their approved conditions and research continues to move forward with the approval of more medications from these classes.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_112_24","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T01:00:09Z","timestamp":1729213209000},"page":"4128-4134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician"],"prefix":"10.4103","volume":"13","author":[{"given":"Abigail","family":"Beard","sequence":"first","affiliation":[{"name":"Heritage College of Osteopathic Medicine, Ohio University, Dublin, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon C.","family":"Trotter","sequence":"additional","affiliation":[{"name":"Heritage College of Osteopathic Medicine, Ohio University, Dublin, Ohio, USA"},{"name":"Dermatologists of Central States, Springfield, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"R1-20250114","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway:Impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"R2-20250114","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"R3-20250114","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.3390\/jcm11154431","article-title":"The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis:A systematic review","volume":"11","author":"Tsiogka","year":"2022","journal-title":"J Clin Med"},{"key":"R4-20250114","first-page":"19","article-title":"JAK-inhibitors in dermatology \u2013small molecules, big impact:Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein","year":"2022","journal-title":"J Deutsche Derma Ges"},{"key":"R5-20250114","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3390\/ijms24043391","article-title":"TYK2 Targeting in immune-mediated inflammatory diseases","volume":"24","author":"Rusi\u00f1ol","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R6-20250114","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41420-022-00927-4","article-title":"Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease","volume":"8","author":"Yin","year":"2022","journal-title":"Cell Death Discov"},{"key":"R14-20250114","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"R15-20250114","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis:Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R16-20250114","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-20250114","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jamadermatol.2019.0008","article-title":"Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis:A systematic review and meta-analysis","volume":"155","author":"Yang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R18-20250114","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2):Results from two replicate double-blind, randomized controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"R19-20250114","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","article-title":"Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis:An integrated analysis from eight randomized clinical trials","volume":"22","author":"King","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R20-20250114","doi-asserted-by":"crossref","first-page":"adv00764","DOI":"10.2340\/actadv.v102.2075","article-title":"Comparative efficacy and safety of monoclonal antibodies and janus kinase inhibitors in moderate-to-severe atopic dermatitis:A systematic review and meta-analysis","volume":"102","author":"Sedeh","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"R21-20250114","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s13555-022-00721-1","article-title":"Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids:Systematic review and network meta-analysis","volume":"12","author":"Silverberg","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R22-20250114","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3390\/jpm13030384","article-title":"A new horizon for atopic dermatitis treatments:JAK inhibitors","volume":"13","author":"Tampa","year":"2023","journal-title":"J Pers Med"},{"key":"R23-20250114","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.3390\/jcm10194307","article-title":"Role of janus kinase inhibitors in therapy of psoriasis","volume":"10","author":"S\u0142uczanowska-G\u0142\u0105bowska","year":"2021","journal-title":"J Clin Med"},{"key":"R24-20250114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors:A review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R25-20250114","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata:A randomized, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"R26-20250114","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s13555-023-01044-5","article-title":"Treatments for moderate-to-severe alopecia areata:A systematic narrative review","volume":"13","author":"Egeberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R27-20250114","doi-asserted-by":"crossref","first-page":"790125","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo:A review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"R28-20250114","first-page":"104499","article-title":"FDA approves ruxolitinib (Opzelura) for vitiligo therapy:A breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"R29-20250114","doi-asserted-by":"crossref","first-page":"790125","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo:A review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"R30-20250114","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R31-20250114","first-page":"18","article-title":"How to explain JAK inhibitor warnings to patients","volume":"43","author":"Scoviak","year":"2022","journal-title":"Dermatol Times"},{"key":"R32-20250114","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors:A consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R33-20250114","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-020-00275-8","article-title":"Frequency of prescription claims for drugs that may interact with janus kinase inhibitors among patients with rheumatoid arthritis in the US","volume":"8","author":"Walton","year":"2021","journal-title":"Rheumatol Ther"}],"updated-by":[{"DOI":"10.4103\/jfmpc.jfmpc_1986_24","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_112_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:46:58Z","timestamp":1787773618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_112_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_112_24","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-01-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}